155 related articles for article (PubMed ID: 35963369)
1. Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study.
Chen B; Zhong J; Li X; Pan F; Ding Y; Zhang Y; Chen H; Liu F; Zhang Z; Zhang L; Drozda R; Oliinyk O; Goh AH; Chen X; Sun X; Rubin DT; Sandborn WJ; Chen M
Gastroenterology; 2022 Dec; 163(6):1555-1568. PubMed ID: 35963369
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
[TBL] [Abstract][Full Text] [Related]
3. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
[TBL] [Abstract][Full Text] [Related]
4. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
5. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Zhao Y; Zhang L; Ding Y; Tao X; Ji C; Dong X; Lu J; Wu L; Wang R; Lu Q; Goh AH; Liu R; Zhang Z; Zhang J
Am J Clin Dermatol; 2021 Nov; 22(6):877-889. PubMed ID: 34374027
[TBL] [Abstract][Full Text] [Related]
7. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Sands BE; Sandborn WJ; Feagan BG; Lichtenstein GR; Zhang H; Strauss R; Szapary P; Johanns J; Panes J; Vermeire S; O'Brien CD; Yang Z; Bertelsen K; Marano C;
J Crohns Colitis; 2018 Nov; 12(10):1158-1169. PubMed ID: 29917064
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
[TBL] [Abstract][Full Text] [Related]
9. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
10. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
Vermeire S; Sands BE; Tilg H; Tulassay Z; Kempinski R; Danese S; Bunganič I; Nitcheu J; Santo J; Scherrer D; Biguenet S; Ehrlich HJ; Steens JM; Gineste P; Sandborn WJ
Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1024-1035. PubMed ID: 36075249
[TBL] [Abstract][Full Text] [Related]
11. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
12. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
Landis MN; Arya M; Smith S; Draelos Z; Usdan L; Tarabar S; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Sikirica V; Xenakis J; Beebe JS
Br J Dermatol; 2022 Dec; 187(6):878-887. PubMed ID: 35986699
[TBL] [Abstract][Full Text] [Related]
14. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme.
Sandborn WJ; Nguyen DD; Beattie DT; Brassil P; Krey W; Woo J; Situ E; Sana R; Sandvik E; Pulido-Rios MT; Bhandari R; Leighton JA; Ganeshappa R; Boyle DL; Abhyankar B; Kleinschek MA; Graham RA; Panes J
J Crohns Colitis; 2020 Sep; 14(9):1202-1213. PubMed ID: 32161949
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
[TBL] [Abstract][Full Text] [Related]
16. Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors.
Goetsch A; D'Amico F; Allocca M; Fiorino G; Furfaro F; Zilli A; Parigi TL; Radice S; Peyrin-Biroulet L; Danese S
Expert Opin Pharmacother; 2023 May; 24(7):849-861. PubMed ID: 37038911
[TBL] [Abstract][Full Text] [Related]
17. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Sandborn WJ; Danese S; Leszczyszyn J; Romatowski J; Altintas E; Peeva E; Hassan-Zahraee M; Vincent MS; Reddy PS; Banfield C; Salganik M; Banerjee A; Gale JD; Hung KE
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2616-2628.e7. PubMed ID: 36623678
[TBL] [Abstract][Full Text] [Related]
18. Etrolizumab for induction of remission in ulcerative colitis.
Rosenfeld G; Parker CE; MacDonald JK; Bressler B
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
[TBL] [Abstract][Full Text] [Related]
19. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
[TBL] [Abstract][Full Text] [Related]
20. Cannabis for the treatment of ulcerative colitis.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
